An MS Pain Trial Had a Negative Initial Comparison and a Favorable Withdrawal Phase
A nabiximols trial in MS-related neuropathic pain missed its initial efficacy endpoints but favored continued treatment in a later randomized withdrawal phase. The phases investigated different populations and treatment questions.
The larger initial phase did not show superiority
The review describes 339 patients receiving add-on THC:CBD spray or placebo for refractory central neuropathic pain associated with multiple sclerosis. At fourteen weeks, 50% and 45%, respectively, met the 30% pain-improvement criterion; that difference was not statistically significant. Mean pain-score changes also did not differ significantly, at −1.93 versus −1.76. Improvement within both groups did not establish a treatment advantage.
The withdrawal phase supplied a narrower finding
Among 58 patients entering a subsequent four-week randomized withdrawal phase, time to treatment failure favored continued nabiximols. The review reports failure in 24% receiving the active spray and 57% receiving placebo, with p = 0.04. This later comparison examined maintenance versus withdrawal in a selected subset, rather than the same question as starting treatment in the full initial trial population.
Read the phases together
The favorable withdrawal finding should not be omitted, but it cannot erase the initial null comparisons or be generalized to every person beginning therapy. Conversely, the initial result does not establish that continued treatment lacked benefit for all selected participants. Report the phase, participant count, endpoint and comparator beside each estimate. The preparation contained both THC and CBD, so the findings also do not isolate a CBD effect. This phase-specific account explains why apparently conflicting summaries of the same trial can arise when different parts of its design are quoted without context.
Related analysis: the broader findings and limitations of this research.
Research cited
The study observations discussed here are reported in the supplied review: Überall (2020). A Review of Scientific Evidence for THC:CBD Oromucosal Spray (Nabiximols) in the Management of Chronic Pain. Journal of Pain Research.
